Molecular Genetics & Genomic Medicine (Jul 2022)

Germline mutations in Chinese ovarian cancer with or without breast cancer

  • Ava Kwong,
  • Cecilia Yuen Sze Ho,
  • Vivian Yvonne Shin,
  • Chun Hang Au,
  • Wing Pan Luk,
  • Ling Hiu Fung,
  • Tsun‐Leung Chan,
  • Karen Kar Loen Chan,
  • Hextan Yuen Sheung Ngan,
  • Edmond Shiu Kwan Ma

DOI
https://doi.org/10.1002/mgg3.1940
Journal volume & issue
Vol. 10, no. 7
pp. n/a – n/a

Abstract

Read online

Abstract Background Ovarian and breast cancers are known to have significant genetic components. Considering the differences in the mutation spectrum across ethnicity, it is important to identify hereditary breast and ovarian cancer (HBOC) genes mutation in Chinese for clinical management. Methods Two cohorts of 451 patients with ovarian cancer only (OV) and 93 patients with both breast and ovarian (BROV) cancers were initially screened for BRCA1, BRCA2, TP53, and PTEN. 109 OV and 43 BROV patients with extensive clinical risk and were being tested negative, were then further characterized by 30‐gene panel analysis. Results Pathogenic BRCA1/2 variants were identified in 45 OV patients and 33 BROV patients, giving a prevalence of 10% and 35.5%, respectively. After the extended screening, mutations in other HBOC genes were identified in an additional 12.8% (14/109) of the OV cohort and 14% (6/43) in the BROV cohort. The most commonly mutated genes in the OV cohort were MSH2 (4.6%) while in the BROV cohort were MSH2 (4.7%) and PALB2 (4.7%). With this extended multigene testing strategy, pathogenic mutations were detected in 12.8% of OV patients (BRCAs: 10%; additional genes: 12.8%) and 40.9% (BRCAs: 35.5%; additional genes: 14%) of BROV patients. Conclusion Extended characterization of the contributions of HBOC genes to OV and BROV patients has significant impacts on further management in patients and their families, expanding the screening net for more asymptomatic individuals.

Keywords